loading
Bristol Myers Squibb Co stock is traded at $43.83, with a volume of 10.10M. It is up +0.00% in the last 24 hours and down -0.75% over the past month. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$43.83
Open:
$43.93
24h Volume:
10.10M
Relative Volume:
0.73
Market Cap:
$89.21B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
17.68
EPS:
2.4784
Net Cash Flow:
$14.58B
1W Performance:
+0.46%
1M Performance:
-0.75%
6M Performance:
-9.98%
1Y Performance:
-17.18%
1-Day Range:
Value
$43.58
$43.94
1-Week Range:
Value
$43.34
$45.23
52-Week Range:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Name
Bristol Myers Squibb Co
Name
Phone
(609) 252-4621
Name
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Employee
34,100
Name
Twitter
@BMSNEWS
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
BMY's Discussions on Twitter

Compare BMY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
43.83 89.21B 47.70B 5.07B 14.58B 2.4784
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-05-25 Downgrade Daiwa Securities Outperform → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Apr-22-25 Initiated Piper Sandler Overweight
Dec-16-24 Upgrade Jefferies Hold → Buy
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-13-24 Upgrade Daiwa Securities Neutral → Outperform
Nov-12-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-25-24 Downgrade Citigroup Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Jul-29-24 Downgrade Barclays Overweight → Equal Weight
Mar-11-24 Downgrade Societe Generale Buy → Hold
Feb-06-24 Downgrade Redburn Atlantic Buy → Neutral
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Nov-15-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-09-23 Initiated Deutsche Bank Hold
Nov-02-23 Downgrade Daiwa Securities Outperform → Neutral
Oct-27-23 Downgrade BMO Capital Markets Outperform → Market Perform
Oct-27-23 Upgrade HSBC Securities Reduce → Hold
Oct-27-23 Downgrade William Blair Outperform → Mkt Perform
Oct-20-23 Resumed UBS Neutral
Jul-14-23 Initiated HSBC Securities Reduce
Jul-10-23 Initiated SVB Securities Market Perform
Jun-28-23 Initiated Daiwa Securities Outperform
Mar-06-23 Initiated Jefferies Hold
Jan-17-23 Initiated Cantor Fitzgerald Overweight
Nov-18-22 Initiated Credit Suisse Neutral
Oct-10-22 Downgrade Guggenheim Buy → Neutral
Sep-14-22 Downgrade Berenberg Buy → Hold
Jun-03-22 Downgrade Raymond James Outperform → Mkt Perform
Apr-06-22 Resumed Morgan Stanley Underweight
Dec-17-21 Initiated Goldman Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Nov-01-21 Downgrade Argus Buy → Hold
Jul-27-21 Resumed Truist Buy
Apr-30-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-13-21 Upgrade Truist Hold → Buy
Nov-16-20 Upgrade Societe Generale Hold → Buy
Nov-10-20 Resumed Bernstein Mkt Perform
Nov-06-20 Downgrade Gabelli & Co Buy → Hold
Oct-19-20 Upgrade Guggenheim Neutral → Buy
Sep-29-20 Initiated Berenberg Buy
Jul-28-20 Initiated Raymond James Outperform
Apr-02-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Jan-06-20 Resumed Citigroup Buy
Dec-13-19 Upgrade Argus Hold → Buy
Nov-22-19 Resumed Morgan Stanley Equal-Weight
Oct-17-19 Resumed BofA/Merrill Buy
Aug-14-19 Upgrade Atlantic Equities Neutral → Overweight
May-28-19 Initiated Goldman Buy
May-20-19 Downgrade Argus Buy → Hold
May-03-19 Upgrade Barclays Equal Weight → Overweight
May-03-19 Resumed JP Morgan Overweight
Jan-15-19 Upgrade Societe Generale Sell → Buy
Oct-22-18 Downgrade Citigroup Buy → Neutral
View All

Bristol Myers Squibb Co Stock (BMY) Latest News

pulisher
03:35 AM

BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛

03:35 AM
pulisher
Oct 24, 2025

Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail

Oct 24, 2025
pulisher
Oct 24, 2025

Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com

Oct 23, 2025
pulisher
Oct 23, 2025

Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS

Oct 23, 2025
pulisher
Oct 23, 2025

Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360

Oct 22, 2025
pulisher
Oct 22, 2025

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool

Oct 22, 2025
pulisher
Oct 21, 2025

Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha

Oct 21, 2025
pulisher
Oct 21, 2025

Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.

Oct 21, 2025
pulisher
Oct 21, 2025

How high can Bristol Myers Squibb Company stock goJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News

Oct 20, 2025
pulisher
Oct 20, 2025

US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters

Oct 20, 2025
pulisher
Oct 20, 2025

Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS

Oct 20, 2025
pulisher
Oct 20, 2025

Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 18, 2025

Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com

Oct 18, 2025
pulisher
Oct 17, 2025

Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com

Oct 17, 2025
pulisher
Oct 16, 2025

Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st

Oct 16, 2025
pulisher
Oct 16, 2025

insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance

Oct 16, 2025
pulisher
Oct 15, 2025

Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView

Oct 15, 2025
pulisher
Oct 15, 2025

What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey

Oct 15, 2025
pulisher
Oct 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace

Oct 15, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com

Oct 14, 2025
pulisher
Oct 14, 2025

insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia

Oct 14, 2025
pulisher
Oct 14, 2025

BMY Collaboration Advances ALS Treatment Development - GuruFocus

Oct 14, 2025
pulisher
Oct 14, 2025

$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech

Oct 14, 2025
pulisher
Oct 14, 2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review

Oct 14, 2025
pulisher
Oct 14, 2025

What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st

Oct 14, 2025
pulisher
Oct 14, 2025

Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma

Oct 14, 2025
pulisher
Oct 14, 2025

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl

Oct 14, 2025
pulisher
Oct 14, 2025

Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Insider Monkey

Oct 13, 2025
pulisher
Oct 13, 2025

Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple

Oct 13, 2025

Bristol Myers Squibb Co Stock (BMY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
$120.94
price up icon 0.17%
$291.76
price down icon 0.39%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
Cap:     |  Volume (24h):